Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake
Authors:
- 27 March 2009
- journal article
- research article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 32 (3) , 228-233
Abstract
Background: Retinoic acid (RA) treatment has been used for redifferentiation of metastatic thyroid neoplasia that have lost radioiodine (131I) uptake with heterogeneous results. Aim: Retrospective analysis of the recovery rate of 1311 uptake after RA treatment in patients from 11 Spanish hospitals. Methods: Twenty-seven patients (14 men, 13 women) with papillary [21], follicular [4], and oncocytic [2] thyroid cancer initially treated with total thyroidectomy plus 131I, and with 131I negative metastatic disease, were given 13-cis RA (0.66–1.5 mg/kg for 5–12 weeks) followed by a therapeutic 131I dose (3700–7400 MBq); 3 months later thyroglobulin levels and computed tomography imaging were performed. Results: In 9 out 27 cases (33%) (8 papillary, 1 follicular) optimal positive 131I scan was observed after RA treatment; in the remaining 18, 10 had a suboptimal uptake (7 papillary, 2 follicular, 1 oncocytic) and in the rest there was no 131I uptake recovery (6 papillary, 1 follicular, 1 oncocytic). In 17 positive responses to RA (either optimal or suboptimal) in which image follow-up was available, decrease or stabilization of metastatic growth was observed in 7, while tumor mass increased at short term in the remaining 10. No major side effects were detected. Conclusion: Quite a high rate of 131I uptake recovery after RA treatment may be obtained in advanced differentiated thyroid cancer, but the potential modification of the natural course of the disease is uncertain. A better biological characterization of these tumors allowing the identification of potential responders to RA may improve the outcome of RA coadjuvant therapy.Keywords
This publication has 27 references indexed in Scilit:
- The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membraneEndocrine-Related Cancer, 2006
- Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinomaInternational Journal of Cancer, 2003
- Management of thyroid cancerThe Lancet Oncology, 2002
- Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Current Approaches to Primary Therapy for Papillary and Follicular Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2001
- Retinoic Acid Redifferentiation Therapy for Thyroid CancerThyroid®, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Redifferentiation therapy-induced radioiodine uptake in thyroid cancer.1998
- Therapy of acute promyelocytic leukemia: all-trans retinoic acid and beyond.1998
- Effects of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived therefromExperimental and Clinical Endocrinology & Diabetes, 1996